OTCM
RADLY
Market cap7.25bUSD
Oct 08, Last price
4.14USD
1D
-0.36%
1Q
10.27%
IPO
-17.92%
Name
Raia Drogasil SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Raia Drogasil SA engages in the retail sale of medicine, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Its stores are supplied by distribution centers located in the states of São Paulo, Rio de Janeiro, Minas Gerais, Paraná, Goiás, Pernambuco, and Bahia. The company was founded in 1905 and is headquartered in Butanta, Brazil.
Key people
Antonio Pipponzi
Chairman of the Board · since 2011
Marcello De Zagottis
Chief Operating Officer, Member of the Executive Board · since 2024
Maria de Souza
Vice President - People, Culture and Sustainability, Member of the Executive Board · since 2019
Melissa Cabral
Vice President of Pharmacy Operations, Member of the Executive Board · since 2024
Antonio Coelho
Vice President - Finance and Administration, Member of the Executive Board · since 2019
Flavio De Moraes Correia
Investor Relations Officer, Member of the Executive Board · since 2024
Juliana Paixao
Commercial Vice President, Member of the Executive Board · since 2024
Bruno Pipponzi
Vice President - Health Business, Member of the Executive Board · since 2019
Renato Raduan
Chief Executive Officer, Member of the Executive Board · since 2024
Fernando Varela
Vice President - Digital Transformation, Member of the Executive Board · since 2019
Eugenio de Zagottis
Director · since 2023
Carlos Dias
Director · since 2011
Renato Dias
Director · since 2002
Paulo Sergio Galvao Filho
Director · since 1994
Plinio Musetti
Director · since 2011
Cristiana Pipponzi
Director
Marco Bonomi
Independent Vice Chairman of the Board · since 2022
Eduardo De Alvarenga
Independent Director · since 2023
Sylvia de Souza Leao Wander
Independent Director · since 2021
Philipp Povel
Independent Director · since 2021
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||